Año 2023 / Volumen 115 / Número 11
Original
The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab

608-614

DOI: 10.17235/reed.2023.9491/2023

Pilar Navajas Hernández, Pilar del Pino Bellido, Laura Lorenzo González, Concepción González Rodríguez, Antonio Pérez Pérez, Federico Argüelles Arias,

Resumen
Background: the success of strategies with earlier anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) have been shadowed by the development of anti-drug antibodies that reduce their effectiveness. The HLA-DQA1*05 allele has been shown to increase the risk of immunogenicity to anti-TNF drugs by approximately two-fold. The negative impact of this allele has not been fully investigated for newer biotherapies. Objective: whether the presence of the HLA-DQA1*05 allele is associated with a reduction of response to ustekinumab and vedolizumab was investigated. Material and methods: the impact of HLA-DQA1*05 on disease activity in 93 patients with IBD, treated with ustekinumab (n = 39) or vedolizumab (n = 54) was investigated in a retrospective cohort study. Treatment response and remission was assessed at 6 and 12 months for ustekinumab, and up to 18 and 24 months for vedolizumab, using Harvey-Bradshaw index (Crohn’s disease) and Mayo score (ulcerative colitis). Results: the HLA-DQA1*05 allele was found in 35.9 % and 38.9 % of patients treated with ustekinumab and vedolizumab, respectively. Clinical response was not affected by the presence of the HLA-DQA1*05 allele for both treatment groups. Conclusions: in contrast to anti-TNF drugs, HLA-DQA1*05 presence does not correlate with the decreased response to ustekinumab or vedolizumab.
Resumen coloquial
Studies suggest that the presence of a genetic allele (HLA-DQA1*05) is implicated in a worse response and development of antibodies to certain biologic therapies, in particular anti-TNFs (the most commonly used drugs in inflammatory bowel disease). Newer drugs used more recently in IBD include Ustekinumab and Vedolizumab. There is no evidence that this genotype is associated with response to these drugs, which is why the aim of this study was to evaluate whether the presence of the HLA-DQA1*05 allele is associated with a reduced response to Ustekinumab and Vedolizumab. To do this, a retrospective study was performed, in which we concluded that the clinical response to these drugs was not affected by the presence of the HLA-DQA1*05 allele in both treatment groups in contrast to the anti-TNF drugs, HLA-DQA1*05 carrier status does not correlate with decreased response to Ustekinumab or Vedolizumab.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Navajas Hernández P, del Pino Bellido P, Lorenzo González L, González Rodríguez C, Pérez Pérez A, Argüelles Arias F, et all. The HLA-DQA1*05 genotype does not influence the clinical response to ustekinumab and vedolizumab. 9491/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 938 veces.
Este artículo ha sido descargado 117 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 25/01/2023

Aceptado: 17/05/2023

Prepublicado: 14/06/2023

Publicado: 13/11/2023

Tiempo de revisión del artículo: 99 días

Tiempo de prepublicación: 140 días

Tiempo de edición del artículo: 292 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas